Data Package Clause Samples

Data Package. Upon Licensee's written request to MPP and submission of relevant access information requested by MPP, Shionogi shall make available to Licensee, on a confidential basis, a discrete data package related to the Compound, the contents of which shall have been determined by Shionogi in its sole discretion. Prior to receiving access to the data package, Licensee may request in writing from MPP, in which event MPP shall provide to Licensee, a high-level summary of topics included in the data package, provided that such summary shall not create any obligation on the part of Shionogi to include any specific piece of information in the data package. Shionogi shall not be required to provide any technical support or technical assistance to a Sublicensee for any reason.

Data Package. Infinity shall deliver to Novartis the following information and materials with respect to such Lead Program (collectively, the “Data Package”): (a) Data evidencing achievement of all Lead Criteria set forth in Section 3.3.2; and (b) The following data for the most potent compound of each Lead Series: (i) [**]; (ii) [**]; (iii) [**]; (iv) [**]and (v) [**].

Data Package. For each Product model the applicable current data package shall include, but is not limited to, flyers, boilerplates technical specification lists, and other pertinent documentation intended for use by the Buyer's customer or support personnel.

Data Package. Data packages shall be prepared to support the design review presentations. The packages for the SPDR and the SCDR shall be structured to be stand-alone packages. However, detailed material (e.g., analyses provided as appendices) provided at the SPDR which has not changed at the SCDR need not be resubmitted. Detailed content shall comply with the requirements given the CDRL descriptions for SPDR and SCDR.

Data Package. On a Reserved Target-by-Reserved Target basis, as soon as reasonably possible following completion of the activities under the applicable Reserved Target Research Plan, which shall, subject to the below, be completed by the Research Completion Deadline, the Parties shall provide the JRC with a data package containing the Development Data generated under the Reserved Target Research Plan and other information necessary for Genmab to evaluate its interest exercising an option with respect to the Reserved Target (“Reserved Target Data Package”). In addition to the Reserved Target Data Package, CureVac shall at the same time provide the LNP Technology License Documentation Package to Genmab. If the Parties cannot reasonably provide such complete Reserved Target Data Package, or if CureVac is unable to provide the LNP Technology License Documentation Package, or if certain activities in the Reserved Target Research Plan are delayed, by the Research Completion Deadline, and unless the Parties mutually agree an extension of the Research Completion Deadline and the Reservation Period (such agreement not to be unreasonably withheld if there are outstanding Development activities required under the Reserved Target Research Plan), the Reservation Period shall be extended to allow Genmab to evaluate its interest in exercising an option pursuant to Section 3.4 by the shorter of (i) [*****] after receipt by the JRC of the complete Reserved Target Data Package and LNP Technology License Documentation Package; or (ii) [*****] after the commencement of the Reservation Period where the corresponding Reserved Target Research Plan relates to a Single Antibody Product and [*****] after commencement of the Reservation Period where the corresponding Reserved Target Research Plan relates to a Cocktail Product.

Data Package. At a Party’s request during the Research Term, but in any event within [***], the other Party shall provide a data package to the requesting Party, which data package will include, to the extent available and in the Control of the other Party: all in-vitro, preclinical and toxicology data and analyses (including electronic or other reasonable access to all raw data) for such Collaboration Target and any Collaboration Compounds Directed to such Collaboration Target, to the fullest extent reasonably possible so as to assist and enable the requesting Party to make its decision on whether to exercise the Lilly Option or NextCure Option, as applicable, with respect thereto (the “Data Package”); provided that the parameters and contents required for any such Data Package shall be identified and included in each applicable Project Plan; provided, further, that, notwithstanding the foregoing, any such Data Package shall only include the data generated until the date of provision of such Data Package to the applicable Party. The Parties may modify the required contents of the Data Package, if mutually agreed. NextCure shall, during the Lilly Option Period for such Collaboration Target, as requested by Lilly, meet with Lilly to discuss such Data Package and any questions Lilly may have with respect thereto, including providing Lilly with such additional information to assist with interpretation of the Data Package as Lilly may reasonably request. Lilly shall, during the NextCure Option Period for such Collaboration Target, as requested by NextCure, meet with NextCure to discuss such Data Package and any questions NextCure may have with respect thereto, including providing NextCure with such additional information to assist with interpretation of the Data Package as NextCure may reasonably request.

Data Package. For each Company Selected Compound, as promptly as possible (and in no event later than any date for the for the delivery thereof specified in the Research Plan or as otherwise agreed by the Parties in writing), SpinCo will assemble and deliver to the Company a Data Package for such Company Selected Compound.

Data Package. 3.1 The Client shall purchase a package of data and/or content relating to Pre-Match Events and In-Play Events from the Supplier (the “Data Package”). The fees for the Data Package are set out in paragraph 5 of this Schedule 1 (Data Package Fee), and those sums shall be included in the invoices submitted under Clause 11. The Supplier will neither make any profit from, nor apply any mark-up to, the costs of data that are charged to the Client in accordance with this Schedule 1. 3.2 The Supplier reserves the right to select the Data and Content Providers that are used, at its sole discretion. 3.3 The Client acknowledges that: ● the events for which data is provided, as described in the table in paragraph ‎‎ 5 of this Schedule 1, may be subject to change at the Supplier’s sole discretion; ● the Supplier’s Data and Content Service costs may increase over time and the Supplier reserves the right to vary the fees (and/or basis upon which the fees are calculated) of any Data and Content Services affected by such cost increases, or exclude any part of the Service at its sole discretion. The Supplier will inform the Client with reasonable advance notice of any such decision. 3.4 Subject to Clause ‎ 14.1, the Supplier will have no liability to provide any part of the Service or for any delay in the provision of any part of the Service which is dependent on Data and Content Services (and may, at its sole discretion, immediately suspend or terminate the provision of the same): ● where the Client does not (i) elect in accordance with paragraph 2.1 to take relevant optional Data and Content Services; (ii) comply with Clause 6.8; (iii) provide the Supplier with reasonable evidence that the Client has complied with the requirements referred to in Clause 6.8; and/or (iv) does not promptly pay the required fees, or states an intention not to pay the required fees, for any relevant Data and Content Services; and/or ● where it is caused by any failure or delay by the Data and Content Providers to provide any data or content.

Data Package. Once a Collaboration Compound completes a POC Trial (and thus becomes a POC Compound), NGM shall, within [*] of such completion, provide a mutually agreed upon data package to Merck, which data package will in any event include: (i) [*]; (ii) [*]; (iii) [*]; (iv) [*]; (v) [*]; (vi) [*], in each case of (i) through (vi), inclusive, to the fullest extent reasonably possible so as to assist and enable Merck to make its decision on whether to exercise the Merck Option with respect thereto; and (vii) an executed statement affirming the representations and warranties in Sections 11.1 and 11.2 remain accurate or otherwise noting any disclosures necessary to make such representations and warranties accurate, which disclosures shall not be considered, of themselves, to be a breach of this Agreement(the “Data Package”). NGM shall, during the Option Period for such POC Compound and, as requested by Merck, meet with Merck to discuss such Data Package and any questions of Merck with respect thereto, including providing Merck with such additional information to assist with interpretation of the Data Package as Merck may reasonably request.